The anesthesia management with remifentanil uses partial antagonist effect of pentazocine for mu opioid receptor

The anesthesia management with remifentanil uses partial antagonist effect of pentazocine for mu opioid receptor - The anesthesia management with remifentanil uses partial antagonist effect of pentazocine for mu opioid receptor

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000039101

Enrollment

Registered

2020-01-10

Start date

2020-01-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing general anesthesia

Interventions

Use pentazocine. Not use pentazocine.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients scheduled for elective surgery requiring general anesthesia. ASA-PS 1-2

Exclusion criteria

Exclusion criteria: ASA-PS >=3 Tha patients who are diagnosised or suspected sleep apnea syndrome

Design outcomes

Primary

Measure	Time frame
The effect that pentazocine has on respiratory depression induced by remifentanil.	—

Secondary

Measure	Time frame
Side effects of pentazocine.	—

Countries

Japan

Contacts

Public ContactHiroto Chikubu

Matsudo city general hospital Anesthesiology

higuneko1@yahoo.co.jp0477122511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026